Home 活动/文摘 文章摘选
Articles
3大致癌因子:肥胖、运动少、不健康饮食 Print E-mail
There are no translations available.

3大致癌因子:肥胖、运动少、不健康饮食

(全文转载自:联合新闻网 【联合晚报╱记者李树人/台北报导】 2014.04.15)


3大致癌因子:肥胖、运动少、不健康饮食

据统计,我国(台湾)是亚洲最爱吃肉的国家,每人年肉类供应量高达70公斤,加上运动量不足,近1300万名19岁以上成年人未达到「333」运动建议标准。国健署首次将肥胖、不健康饮食、缺乏运动列入我国新兴致癌因子,认为近年来,国人大肠癌及女性乳癌新增人数高居不下,就是与这三项因子有关。

国民健康署今天公布最新癌症登记报告,署长邱淑媞认为,台湾癌症发生人数持续增加的主要原因是高龄化、生活型态改变、肥胖人口增加及癌症筛检推广。

统计显示,国人脂肪摄取过多,与日、韩、香港、中国大陆以及东南亚国家相较,每人年肉类供应量高居第一。爱吃肉却不太运动,与OECD(经济合作暨发展组织)34个成员国相较,我国男性不运动比率居第一名,女性则排第二。

中研院生物医学研究所研究员潘文涵指出,肥胖、不健康饮食及缺乏运动等三大致癌因子关係密切,其中以不健康饮食的影响层面最广。长期摄取过多脂肪及热量,蔬果摄取不足,易导致正常细胞DNA损伤、修复能力变差,提高癌细胞突变机率。

Read more...
 
美国NCI抗癌药典 收录中药複方 Print E-mail
There are no translations available.

美国NCI抗癌药典 收录中药複方

(全文转载自:健康医疗网/记者关嘉庆报导 2014年1月13日)


美国NCI抗癌药典 收录中药複方

(健康医疗网/记者关嘉庆报导)中药典籍博大精深,从古代的神农嚐百草,到李时珍的本草纲目,以致于近代的中药典,都对中药有很详尽的阐述;然而,不只是华人,目前全世界都对中药方剂有所关注,甚至于已有中药複方,已被美国国家癌症研究院(National Cancer Institute NCI)列入抗癌药物药典名单之中!

美国国家癌症研究院(NCI)将一中药複方列入抗癌药物药典,其从许多科学验证证明得知,此中药複方为具有抗氧化及免疫调节与抗肿瘤活性作用的口服中草药液剂,此複方含有包括冬虫夏草、白花蛇舌草、猪苓、黄耆、人参、广霍香、白朮、女贞子等十四种中草药;且目前仍不断在进行更广泛之研发。

Read more...
 
癌干细胞除不了?!中药複方可抑制 Print E-mail
There are no translations available.

癌干细胞除不了?!中药複方可抑制

(全文转载自:健康医疗网/记者关嘉庆报导 2013/12/19)


癌干细胞除不了?!中药複方可抑制

健康医疗网/记者关嘉庆报导 2013/12/19

根据国健署癌症登记资料显示,癌症已蝉联31年高居国人十大死因首位!由于医学研究发现,癌症的治疗,若是无法将癌干细胞清除,则癌症就会「春风吹又生」,而再度复发;因此,医界目前都在积极研究如何有效杀死癌干细胞。而根据一项实验室研究结果指出,包含冬虫夏草、白花蛇舌草、猪苓,黄芪,人参等14个中药材的中药複方口服液剂,竟可以抑制及清除癌干细胞,论文也已发表在国际着名期刊;该项癌干细胞实验研究结果引起各界瞩目。

此中药複方实验研究主持人、万芳医院癌症中心副主任及血液肿瘤科主任赖基铭医师表示,台湾癌症发生率持续在增加,虽然医学进步,但是死亡率却未见下降,主要的困难即在于治疗失败;很多癌症在手术、放疗和化疗后,仍然出现转移和复发,其中最重要的原因导因于残留的癌干细胞。

Read more...
 
中药治疗优势‧“让白血球杀癌细胞” Print E-mail
There are no translations available.

檳城‧孙苓献:中药治疗优势‧“让白血球杀癌细胞”

(全文转载自:星洲日报【大北马】报导 图:星洲日报 2013-10-13)


檳城‧孙苓献:中药治疗优势‧“让白血球杀癌细胞

(檳城)来自台湾的中西医结合肿瘤专科医生孙苓献认为,让身体的白血球杀癌细胞,比任何治癌药物好。这就是中药治癌的优势。

他在余仁生、东保企业、天仙液,和星洲日报联办的“你是癌症候选人吗?”讲座会,讲解以中药为主的癌症疗法。

孙苓献是天仙液集团抗癌新药临床试验医务总监,过去14年一直进行中药治癌的研究,发现中医在这方面有协同的加乘作用。

他也和美国、日本、台湾、香港等国家或地区的研究机构合作,进行中药治癌临床研究。

Read more...
 
Treatment may fuel cancer's spread, study finds Print E-mail

Treatment may fuel cancer's spread, study finds

(Reuters) - Treating cancer with surgery, chemotherapy or radiation may sometimes cause tumors to spread and U.S. researchers said on Thursday they may have nailed down one of the causes -- a compound called TGF-beta.

Tests in mice show that using the chemotherapy drug doxorubicin or radiation both raised levels of TGF-beta, which in turn helped breast cancer tumors spread to the lung.

But using an antibody to block TGF-beta stopped the process, Dr. Carlos Arteaga and colleagues at Vanderbilt University in Tennessee reported.

Developing drugs that block TGF-beta might help prevent cancer from recurring, Arteaga's team reports in the May issue of the Journal of Clinical Investigation.

"The repopulation and progression of tumors after anti-cancer therapy is a well-recognized phenomenon," the researchers wrote. "It has been shown to occur following radiotherapy, chemotherapy, and surgery."

Cancer experts have wondered if the so-called primary tumor -- the first and biggest tumor -- might somehow suppress the growth of other tumors, and that removing or destroying the first tumor might allow other, undetectable, tumors to then grow.

TGF-beta, which is involved in both the growth and suppression of tumors, may hold part of the answer, Arteaga's team said.

When mice infected with human breast cancer cells were treated with radiation or doxorubicin, they had higher levels of TGF-beta in their blood. They also had more tiny tumor cells in their blood, and these cells metastasized, or spread, to the lungs.

When the mice were treated with an antibody that suppresses TGF-beta, the spread stopped. And this spreading process did not occur at all in mice bred to lack the TGF-beta protein.

"We wondered then if TGF-beta induced by anti-cancer therapies can serve as a survival signal for tumor cells, thus allowing them to withstand therapy and later recur," Arteaga said in a statement.

His team is now testing TGF-beta levels in the blood of breast cancer patients.

"We'll be looking to see in what proportion of patients the serum and tumor TGF-beta goes up, and whether the increase correlates with the inability of the therapy to eliminate the cancer in the breast," Arteaga said.

Higher levels of TGF-beta after treatment may be a way to predict which patients are likely to have their cancer come back after treatment, Arteaga said.

His team is also testing drugs that interfere with TGF-beta to see if they improve survival.

"It probably isn't just TGF-beta that is having this effect," Arteaga said. Many other compounds, including some immune system signaling chemicals, are also associated with tumor spread and growth.

"TGF-beta may be just the tip of the iceberg," Arteaga said.

http://www.reuters.com/article/2007/04/06/us-cancer-spread-idUSN0523151220070406)

Read more...
 
<< Start < Prev 1 2 3 4 Next > End >>

Page 1 of 4

© 2007-2014 Tombo Enterprise Sdn Bhd. Design by Aftersix Design Studio